# Pluri Inc. (PLUR)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $14M  
**Price:** $2.26 (-5.04%)

> Pluri Inc. is a biotechnology company focusing on cell-based therapeutics and technology-driven innovations to address complex medical conditions. The primary function of Pluri is to harness advanced cell-production technologies to develop a wide array of potential therapies that may transform treatment modalities across various sectors. Pluri's expertise lies in using proprietary 3D cell culture platforms to cultivate placental cells, which are then utilized in regenerative medicine applications. These applications have significant implications for industries including orthopedics, cardiovascular health, and autoimmune diseases. The company's innovative approach seeks to provide scalable and sustainable solutions in tissue engineering and organ regeneration, aiming to meet unmet medical needs globally. Pluri Inc.'s commitment to research and development in biotechnology underlines its pivotal role in pioneering new therapeutic strategies, making it a significant entity within the healthcare and life sciences sectors. Established to impact global health, Pluri continues to explore a dynamic intersection between cutting-edge technology and medical sciences, contributing to a potential shift in how chronic illnesses and acute health challenges are managed.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1M | $654,000 | -$22M | -$23M | — |
| 2024 | $326,000 | $322,000 | -$22M | -$21M | — |
| 2023 | $287,000 | $278,000 | -$27M | -$28M | — |
| 2022 | $234,000 | $234,000 | -$42M | -$41M | — |
| 2020 | $23,000 | $23,000 | -$29M | -$29M | — |
| 2019 | $54,000 | $52,000 | -$36M | -$35M | — |
| 2018 | $50,000 | $48,000 | -$34M | -$26M | — |
| 2016 | $3M | $3M | -$23M | -$23M | — |
| 2015 | $379,000 | $366,000 | -$25M | -$25M | — |
| 2014 | $379,000 | $368,000 | -$28M | -$27M | — |
| 2013 | $679,000 | $659,000 | -$22M | -$21M | — |
| 2012 | $716,000 | $695,000 | -$15M | -$15M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $39M | $46M | -$7M | $6M | — |
| 2024 | $40M | $39M | $96,000 | $7M | — |
| 2023 | $51M | $37M | $13M | $5M | — |
| 2022 | $68M | $38M | $30M | $10M | — |
| 2020 | $66M | $9M | $56M | $8M | — |
| 2019 | $31M | $9M | $22M | $4M | — |
| 2018 | $39M | $10M | $29M | $9M | — |
| 2016 | $46M | $8M | $38M | $6M | — |
| 2015 | $68M | $10M | $58M | $23M | — |
| 2014 | $74M | $12M | $62M | $4M | — |
| 2013 | $68M | $11M | $57M | $9M | — |
| 2012 | $47M | $10M | $38M | $9M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$18M | $2M | -$20M |
| 2024 | -$18M | $323,000 | -$18M |
| 2023 | -$23M | $262,000 | -$23M |
| 2022 | -$37M | $280,000 | -$37M |
| 2021 | -$31M | $373,000 | -$31M |
| 2020 | -$26M | $270,000 | -$27M |
| 2019 | -$29M | $239,000 | -$30M |
| 2018 | -$21M | $342,000 | -$22M |
| 2017 | -$22M | $378,000 | -$22M |
| 2016 | -$19M | $2M | -$20M |
| 2015 | -$21M | $831,000 | -$21M |
| 2013 | -$17M | $4M | -$21M |
| 2012 | -$3M | $1M | -$5M |
| 2011 | -$6M | $962,000 | -$7M |
| 2010 | -$5M | $389,000 | -$6M |

Source: [CompaniesByCap](https://companiesbycap.com/company/PLUR)